FDA Advisory Committees Are Platform For Politicized Discussion, Former Counsel Troy Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee members are using the meetings to “bash the agency,” Troy said.
You may also be interested in...
Zarnestra Phase III Data Needed Pre-Approval, Oncology Committee Says
FDA's Oncologic Drugs Advisory Committee votes 7 to 4 against recommending accelerated approval of J&J's tipifarnib. Data from the Phase III trial are necessary to identify the appropriate patient population for the oncologic, members say.
"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says
Although noting that data suggesting a cancer risk from the topical eczema treatments is not definitive, the panel concludes that a black box warning is the best approach to discourage off-label use. A medication guide should also be mandated, the committee says.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.